| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA968: Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) |
|
Medicine details |
|
| Medicine name | melphalan flufenamide (Pepaxti®) |
| Formulation | 20 mg powder for concentrate for solution for infusion |
| Reference number | 4081 |
| Indication | In combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one antiCD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation |
| Company | Oncopeptides AB |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 25/04/2024 |
| NICE guidance | |